Khalife Wissam I, Kogoj Polonca, Kar Biswajit
Department of Cardiology, Division of Heart Failure/Cardiac Transplantation, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
J Heart Lung Transplant. 2007 Jun;26(6):652-7. doi: 10.1016/j.healun.2007.02.010. Epub 2007 Apr 16.
Sirolimus is a well-known, potent immunosuppressant that is widely used in solid-organ transplantation, but it is not without potential side effects. A rare but devastating adverse effect is sirolimus-associated pulmonary toxicity. We report a case of sirolimus-induced diffuse alveolar hemorrhage confirmed by bronchoscopic findings (after other possible etiologies were ruled out) and by clinical and radiographic resolution of the pulmonary signs and symptoms a few days after sirolimus administration was stopped. This case and the existing literature on this topic suggest that sirolimus-induced pulmonary toxicity should be suspected in any patient taking immunosuppressants and who develops unexplained pulmonary symptoms.
西罗莫司是一种广为人知的强效免疫抑制剂，广泛用于实体器官移植，但它并非没有潜在副作用。一种罕见但极具破坏性的不良反应是西罗莫司相关的肺部毒性。我们报告了一例经支气管镜检查结果证实（排除其他可能病因后）的西罗莫司诱发的弥漫性肺泡出血病例，该病例在停用西罗莫司几天后，肺部体征和症状在临床和影像学上得到缓解。该病例及关于此主题的现有文献表明，任何服用免疫抑制剂且出现无法解释的肺部症状的患者都应怀疑西罗莫司诱发的肺部毒性。
